First patients test experimental cancer drug in groundbreaking trial
NCT ID NCT05948826
Summary
This is the first time researchers are testing the experimental drug TORL-3-600 in people. The study aims to find a safe dose and see how the body handles the drug in 70 patients with advanced solid tumors, including colorectal cancer. It is an early safety study, not a cure, and will check for side effects and early signs of whether the drug helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fort Wayne Medical Oncology and Hematology Inc.
Fort Wayne, Indiana, 46845, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute-Tennessee
Nashville, Tennessee, 37203, United States
-
UCLA - JCCC Clinical Research Unit
Los Angeles, California, 90095, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine-Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.